Xing Yu

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 4

Top Topics

Induced Apoptosis

Endoplasmic Reticulum

Small Cell Lung Cancer

Top Venues

Cancer gene therapy

Nature chemical biology

Oxidative medicine and cellular longevity

University of Queensland (MSC)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Queensland

Australia

MSC

Griffith University

Australia

PHD

Central South University

China

BSC

Publications

Fengyan Yuan, Huiqin Zhou, Chongyang Liu, Yi Wang, Jing Quan, Jie Liu, Hao Li, Mark von Itzstein, Xing Yu
Heparanase interacting BCLAF1 to promote the development and drug resistance of ICC through the PERK/eIF2α pathway. Cancer gene therapy 31 (6) (2024)
Fengyan Yuan, Huiqin Zhou, Chongyang Liu, Yi Wang, Jing Quan, Jie Liu, Hao Li, Mark von Itzstein, Xing Yu
Heparanase interacting BCLAF1 to promote the development and drug resistance of ICC through the PERK/eIF2α pathway. Cancer gene therapy (2024)
Fengyan Yuan, Huiqin Zhou, Chongyang Liu, Yi Wang, Jing Quan, Jie Liu, Hao Li, Mark von Itzstein, Xing Yu
Heparanase interacting BCLAF1 to promote the development and drug resistance of ICC through the PERK/eIF2α pathway. Cancer gene therapy 31 (6) (2024)
Yujing Zhang, Gang Yang, Shuai Huang, Xinyue Yang, Fengyan Yuan, Yinghui Song, Sulai Liu, Xing Yu
Regulation of Cr(VI)-Induced Premature Senescence in L02 Hepatocytes by ROS-Ca 2+ -NF- κ B Signaling. Oxidative medicine and cellular longevity 2022 (2022)
Lisa Bohlmann, Gregory D Tredwell, Xing Yu, Chih-Wei Chang, Thomas Haselhorst, Moritz Winger, Jeffrey C Dyason, Robin J Thomson, Joe Tiralongo, Ifor R Beacham, Helen Blanchard, Mark von Itzstein
Functional and structural characterization of a heparanase. Nature chemical biology 11 (12) (2015)